BioVie Says Phase 2 SUNRISE-PD Trial Of Bezisterim In Early Parkinson's Disease Met Prespecified Endpoints, Showing Statistically Significant Motor And Non-Motor Improvements vs. Placebo

뉴스 본문을 불러오고 있어요.

BioVie Says Phase 2 SUNRISE-PD Trial Of Bezisterim In Early Parkinson's Disease Met Prespecified Endpoints, Showing Statistically Significant Motor And Non-Motor Improvements vs. Placebo | 웨이프 WAPE

BioVie Says Phase 2 SUNRISE-PD Trial Of Bezisterim In Early Parkinson's Disease Met Prespecified Endpoints, Showing Statistically Significant Motor And Non-Motor Improvements vs. Placebo

기사 요약

관련 종목

댓글 —